# UBS

Type: Company (UBS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ubs
Canonical HTML page: https://getbiobrief.com/entity/ubs

## Recent coverage (2 stories)

### Abbott Beats Q2 with $12.59B Revenue, Analysts Raise PT to $134; UNH Also Surges
2026-07-25 20:28:16 · Sentiment: Positive · Impact: 7/10 · Sources: 1

Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector.
Full story: https://getbiobrief.com/story/abbott-unh-q2-2026-beat-analyst-target-hikes-bio

### US Lawmakers Sound Alarm Over China’s Growing Dominance in Pharma Supply Chain
2026-03-19 00:21:57 · Sentiment: Negative · Impact: 8/10 · Sources: 3

The House Select Committee on China has warned that Beijing is executing a long-term strategy to dominate the global pharmaceutical market, mirroring its tactics in the rare earth and EV sectors. With China's drug and medical device revenue projected to reach $2.1 trillion by 2030, US officials are calling for urgent action to reduce reliance on Chinese-made active pharmaceutical ingredients.
Full story: https://getbiobrief.com/story/us-china-pharma-supply-chain-dependence

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.